Merck's Ezetimibe Faces Reimbursement Threat In Europe
This article was originally published in The Pink Sheet Daily
Results from the ENHANCE and ARBITER 6-HALTS trials may finally mean reduced coverage in Germany and the U.K.
You may also be interested in...
Economic austerity and the resulting pressure on health care spend leaves little room for maneuver among Europe’s health technology assessment agencies.
Lipitor's European sales won't all disappear overnight, But the strong post-patent performance in Spain isunlikely to be replicated either.
A positive outcome in the SHARP study is good news for Merck, but questions still remain about the efficacy of Vytorin compared to older statins.